PL3917626T3 - Dwutrybowy radioznacznik i terapeutyk wiążący psma - Google Patents

Dwutrybowy radioznacznik i terapeutyk wiążący psma

Info

Publication number
PL3917626T3
PL3917626T3 PL20702636.0T PL20702636T PL3917626T3 PL 3917626 T3 PL3917626 T3 PL 3917626T3 PL 20702636 T PL20702636 T PL 20702636T PL 3917626 T3 PL3917626 T3 PL 3917626T3
Authority
PL
Poland
Prior art keywords
radiotractor
psma
dual
mode
binding therapeutic
Prior art date
Application number
PL20702636.0T
Other languages
English (en)
Inventor
Alexander Josef WURZER
Hans-Jürgen Wester
Matthias Johannes EIBER
Original Assignee
Technische Universität München
Technische Universität München - Klinikum Rechts Der Isar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technische Universität München, Technische Universität München - Klinikum Rechts Der Isar filed Critical Technische Universität München
Publication of PL3917626T3 publication Critical patent/PL3917626T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Circuits Of Receivers In General (AREA)
  • Nuclear Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Toys (AREA)
  • Electrotherapy Devices (AREA)
PL20702636.0T 2019-01-30 2020-01-30 Dwutrybowy radioznacznik i terapeutyk wiążący psma PL3917626T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19154500 2019-01-30
PCT/EP2020/052248 WO2020157177A1 (en) 2019-01-30 2020-01-30 Psma binding dual mode radiotracer and therapeutic

Publications (1)

Publication Number Publication Date
PL3917626T3 true PL3917626T3 (pl) 2023-11-27

Family

ID=65268810

Family Applications (2)

Application Number Title Priority Date Filing Date
PL23167668.5T PL4249456T3 (pl) 2019-01-30 2020-01-30 Radioznacznik i środek terapeutyczny wiążący psma o podwójnym działaniu
PL20702636.0T PL3917626T3 (pl) 2019-01-30 2020-01-30 Dwutrybowy radioznacznik i terapeutyk wiążący psma

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL23167668.5T PL4249456T3 (pl) 2019-01-30 2020-01-30 Radioznacznik i środek terapeutyczny wiążący psma o podwójnym działaniu

Country Status (19)

Country Link
US (2) US12357711B2 (pl)
EP (2) EP4249456B1 (pl)
JP (2) JP7528100B2 (pl)
KR (1) KR102850587B1 (pl)
CN (2) CN116675730A (pl)
AU (2) AU2020213678B2 (pl)
BR (1) BR112021014933A2 (pl)
CA (1) CA3128401A1 (pl)
DK (2) DK3917626T3 (pl)
EA (1) EA202191691A1 (pl)
ES (2) ES2953196T3 (pl)
FI (2) FI3917626T3 (pl)
HU (2) HUE063038T2 (pl)
IL (2) IL303421A (pl)
MX (1) MX2021008999A (pl)
PL (2) PL4249456T3 (pl)
PT (2) PT4249456T (pl)
SG (1) SG11202108109RA (pl)
WO (1) WO2020157177A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240027896A (ko) 2017-07-28 2024-03-04 테크니쉐 우니베르지테트 뮌헨 이중 모드 방사성 트레이서 및 치료법
WO2020157177A1 (en) * 2019-01-30 2020-08-06 Technische Universität München Psma binding dual mode radiotracer and therapeutic
GB202005282D0 (en) 2020-04-09 2020-05-27 Blue Earth Diagnostics Ltd Pharmaceutical Formulations
JP2023539990A (ja) * 2020-07-13 2023-09-21 ポイント バイオファーマ インコーポレイテッド 放射性薬剤および方法
EP4185336A1 (en) * 2020-07-23 2023-05-31 Technische Universität München Silicon-containing ligand compounds
EP4023250A1 (en) * 2021-01-04 2022-07-06 Technische Universität München Dual mode radiotracer and -therapeutics
IL305134A (en) * 2021-02-15 2023-10-01 Technische Universit?T M?Nchen Dual mode radio and medical tracker
GB202109922D0 (en) 2021-07-09 2021-08-25 Blue Earth Diagnostics Ltd Radiotracers and therapeutics binding to fibroblast activation protein (fap)
US20250313579A1 (en) * 2021-08-05 2025-10-09 Technische Universität München Ligand compounds comprising a chelating group as a bridging group
GB202113646D0 (en) 2021-09-24 2021-11-10 Blue Earth Diagnostics Ltd Method of preparation of 18F labelled silyl-fluoride compounds
US20230149569A1 (en) * 2021-09-28 2023-05-18 Antelope Surgical Solutions, Inc. Multifunctional compounds for use in medical imaging and therapy
GB202207372D0 (en) 2022-05-19 2022-07-06 Blue Earth Diagnostics Ltd Synthesis of fluorosilyl compounds
GB202316239D0 (en) 2023-10-24 2023-12-06 Blue Earth Diagnostics Ltd Therapeutic combination
GB202318958D0 (en) * 2023-12-12 2024-01-24 King S College London Compound

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7682601B2 (en) * 2003-04-15 2010-03-23 Mallinckrodt Inc. Bifunctional tridentate pyrazolyl containing ligands for re and tc tricarbonyl complexes
CN1774268A (zh) * 2003-04-15 2006-05-17 马林克罗特公司 用于铼和锝的三羰基络合物的双功能三齿的含吡唑基配体
ES2684322T3 (es) * 2006-11-08 2018-10-02 Molecular Insight Pharmaceuticals, Inc. Heterodímeros de ácido glutámico
JPWO2011040574A1 (ja) * 2009-09-30 2013-02-28 国立大学法人京都大学 アゼチジニルメトキシピリジン誘導体の製造方法及びその使用
NZ612327A (en) * 2010-12-22 2015-03-27 Ge Healthcare Ltd Her2 binding peptides labelled with a 18f - containing organosilicon compound
CN102626522B (zh) * 2012-04-12 2014-09-10 韩彦江 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物
AU2014336638C1 (en) * 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3209336B1 (en) 2014-10-20 2019-12-11 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
KR102724812B1 (ko) * 2017-04-05 2024-11-01 코넬 유니버시티 영상화 및 항종양 치료요법에 유용한 조정 가능한 약동학을 갖는 삼작용성 작제물
KR20240027896A (ko) 2017-07-28 2024-03-04 테크니쉐 우니베르지테트 뮌헨 이중 모드 방사성 트레이서 및 치료법
DK3723815T3 (da) * 2017-12-11 2022-07-11 Univ Muenchen Tech PSMA ligander til billeddannelse og endoradioterapi
WO2020157177A1 (en) * 2019-01-30 2020-08-06 Technische Universität München Psma binding dual mode radiotracer and therapeutic

Also Published As

Publication number Publication date
EP4249456A2 (en) 2023-09-27
IL303421A (en) 2023-08-01
EP4249456A3 (en) 2023-10-11
CA3128401A1 (en) 2020-08-06
EP4249456B1 (en) 2024-09-04
CN116675730A (zh) 2023-09-01
SG11202108109RA (en) 2021-08-30
KR20210153037A (ko) 2021-12-16
EP3917626B1 (en) 2023-05-31
PL4249456T3 (pl) 2025-03-31
JP7528100B2 (ja) 2024-08-05
JP2024073651A (ja) 2024-05-29
JP7763885B2 (ja) 2025-11-04
JP2022523727A (ja) 2022-04-26
WO2020157177A1 (en) 2020-08-06
BR112021014933A2 (pt) 2021-10-05
MX2021008999A (es) 2021-11-04
HUE063038T2 (hu) 2023-12-28
CN113677400A (zh) 2021-11-19
ES2953196T3 (es) 2023-11-08
CN113677400B (zh) 2023-12-01
AU2023203501A1 (en) 2023-07-06
HUE069264T2 (hu) 2025-02-28
FI3917626T3 (fi) 2023-08-17
DK4249456T3 (da) 2024-12-02
EP3917626A1 (en) 2021-12-08
EA202191691A1 (ru) 2021-11-01
KR102850587B1 (ko) 2025-08-27
DK3917626T3 (da) 2023-08-28
IL284958A (en) 2021-09-30
PT3917626T (pt) 2023-08-23
AU2023203501B2 (en) 2024-11-14
ES2995872T3 (en) 2025-02-11
AU2020213678A1 (en) 2021-08-12
US20250295819A1 (en) 2025-09-25
FI4249456T3 (fi) 2024-12-07
IL284958B2 (en) 2026-05-01
US12357711B2 (en) 2025-07-15
US20220096668A1 (en) 2022-03-31
AU2020213678B2 (en) 2024-05-30
PT4249456T (pt) 2024-12-02
IL284958B1 (en) 2026-01-01

Similar Documents

Publication Publication Date Title
DK3947375T3 (da) Imidazolonylquinolinforbindelser og terapeutiske anvendelser deraf
EP3920763A4 (en) SKIN CARE DEVICES
JP1662410S (ja) 患者インターフェース
EP3802802A4 (en) CELLULAR THERAPY
JP1655460S (ja) ポータブルチェアー
IL291486A (en) Therapeutic conjugates
DK3917626T3 (da) Psma-bindende dualmodusradiotracer og terapeutika
EP3999156A4 (en) PATIENT INTERFACE
EP3735463A4 (en) Cytotoxicity-inducing therapeutic agent
EP4169571C0 (en) THERAPY DEVICE
EP4003475C0 (en) PATIENT INTERFACE
EP3781576C0 (en) BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES
EP4266641B1 (en) CONFIGURATION METHOD FOR LINKAGE AND CONTROLLER
EP3946535A4 (en) PATIENT INTERFACE
EP4041064A4 (en) A medical therapeutic device
IL292502A (en) Therapeutic methods using vadadustat
EP3741296A4 (en) BIOELECTRODE
IL283900A (en) Pharmaceutical combinations
EP4028096A4 (en) Patient interface
EP4013440A4 (en) THERAPEUTIC PEPTIDES
EP3990078B1 (en) PATIENT INTERFACE
EP3764973A4 (en) ENTERIC SOFT ENVELOPE CAPSULES
EP3962528A4 (en) Therapeutic combinations comprising anti-cd123 immunoconjugates
EP4034113A4 (en) THERAPEUTIC FORMULATIONS AND THEIR USES
EP3927328A4 (en) INHALABLE THERAPEUTIC AGENT